Thank God the masses have finally started to catch on that they're being mass murdered under the cover of a giant lie & it's most satisfying to see DeathJabb stocks plummeting.
I think all of you brilliant researchers should get together & secure all your data & research onto the Blockchain because we know they have Cyber Polygon up their sleeve which they plan to unleash to take the internet down under some lie & they'll probably use that to wipe a load of websites & info forever - don't let them, this info needs to be held in perpetuity for mankind for those who come after to never forget what was done to us & stop these evil bastards ever trying it again
A few days later I posted a link to a Pfizer document on the mouse biodistribution study for the covid "vaccine" and got a removal notice that I violated their community standards and if I had repeated violations they would shut my page down. This was a document ordered released by a court. Unbelievable crap.
I expect the price will go down again on Monday as they’ve halved their EPS guidance after hours on Friday.
Pfizer also announced additional clarity on its full-year 2023 outlook for its COVID products – Comirnaty and Paxlovid. Clarity on the underlying vaccination and treatment rates will be observed by year end and will set a reliable base for the prediction of future product utilization.
As previously announced, the European Union (EU) contract for Comirnaty supply was renegotiated with amended purchasing obligations through 2026. The U.S. market for Comirnaty transitioned to commercially available product in September 2023. Due to the recent commencement of the fall vaccination period, the outlook for year-end vaccination rates and market shares requires more time for more determinable estimates.
As previously announced, Paxlovid also received full NDA approval from the FDA earlier this year. The global utilization rates for Paxlovid are currently trending slightly above last year’s utilization but lower than our original expectations.
Launches Cost Realignment Program
In addition, in the fourth quarter of 2023, Pfizer announced that the company has launched a multi-year, enterprise-wide cost realignment program that will realign its costs with its longer-term revenue expectations. The program is expected to deliver targeted savings of at least $3.5 billion, of which $1.0 billion is expected to be realized in 2023 and an additional $2.5 billion is expected to be realized in 2024. The one-time costs to achieve the savings associated with the new cost realignment program are expected to be approximately $3.0 billion, of which the majority is expected to be cash. These costs will primarily include severance and implementation costs. Pfizer will continue to refine the estimated targeted savings and their associated costs over the remainder of the year and will incorporate them into its full-year guidance for 2024.
Updates Full-Year 2023 Revenue and Adjusted(2) Diluted EPS Guidance(1) Ranges
Pfizer also announced that it now anticipates full-year 2023 revenues to be in the range of $58.0 to $61.0 billion, versus its previous guidance range of $67.0 to $70.0 billion solely due to its COVID products. Full-year 2023 revenues for Paxlovid and Comirnaty are expected to be approximately $12.5 billion, a decline of $9.0 billion versus original expectations. The company is reducing its full-year 2023 revenue expectations for Paxlovid by approximately $7.0 billion which includes a non-cash $4.2 billion revenue reversal for the return of the 7.9 million treatment courses of EUA-labeled U.S. government inventory, as well as the delayed commercialization to January 2024 versus our previous expectation of commercialization in the second half of 2023. The company is also reducing its full-year 2023 revenue expectations for Comirnaty by approximately $2.0 billion due to lower-than-expected vaccination rates.
Pfizer’s non-COVID products remain on track to achieve an expected 6% to 8% operational revenue growth year over year in 2023.
Due to lower-than-expected utilization for our COVID products, Pfizer recorded a non-cash charge of $5.5 billion to Cost of Goods Sold in the third quarter of 2023 primarily related to inventory write-offs for Paxlovid of $4.6 billion and to a lesser extent for inventory write-offs and other charges for Comirnaty of $0.9 billion.
The company expects to deliver approximately $1.0 billion in savings in 2023 through its cost realignment program.
Revised guidance also reflects anticipated improvement in our Effective Tax Rate on Adjusted(2) Income for 2023 from approximately 15% in our original guidance to approximately 12%.
Due to the aforementioned items, the company now expects full-year 2023 Adjusted(2) diluted EPS to be in the range of $1.45 to $1.65 versus its original guidance range of $3.25 to $3.45.
I object to the framing of SV40 as a “contaminant” the exact same way it was done with the polio vaccines. It is an intentionally included compound designed to cause cancer, just as it is doing.
Thank God the masses have finally started to catch on that they're being mass murdered under the cover of a giant lie & it's most satisfying to see DeathJabb stocks plummeting.
I think all of you brilliant researchers should get together & secure all your data & research onto the Blockchain because we know they have Cyber Polygon up their sleeve which they plan to unleash to take the internet down under some lie & they'll probably use that to wipe a load of websites & info forever - don't let them, this info needs to be held in perpetuity for mankind for those who come after to never forget what was done to us & stop these evil bastards ever trying it again
I posted a video of Dr. Buckhaults Senate Testimony on Facebook and within an hour had a "fact check" saying it was partly false and directing me to the following link: https://healthfeedback.org/claimreview/claim-covid-19-mrna-vaccines-dna-contaminants-study-unknown-provenance-no-evidence-covid-19-mrna-vaccines-alter-dna-people/
A few days later I posted a link to a Pfizer document on the mouse biodistribution study for the covid "vaccine" and got a removal notice that I violated their community standards and if I had repeated violations they would shut my page down. This was a document ordered released by a court. Unbelievable crap.
Ok, I’ll be that guy. It’s sicced.
“sicked their FackChokers”
Do like FackChokers since what the fack do they think they are?
Yet over on Stat News...the “frontline of healthcare”, they have a fresh article telling us, “Yes, Everyone Should get An Updated C19 Vaccine”
Number 1 reason they mention, “There is little downside, they are safe and effective”!!!
The gaslighting and brainwashing continue unabated.
https://www.statnews.com/2023/10/13/updated-covid-vaccine-for-everyone/
No one serious still contends there is no DNA in the injectables ergo fact chokers unserious as well.
Do you mean "contests"?
No, I mean contends. As in, no one serious is still pretending there is no DNA in the shots.
Oh, yeah ~ I see now, there is a "no" there! I shouldn't try to read/type past my bedtime. Sorry! ;)
Thank you Kevin. It takes time but the truth always comes out. Peace.
I expect the price will go down again on Monday as they’ve halved their EPS guidance after hours on Friday.
Pfizer also announced additional clarity on its full-year 2023 outlook for its COVID products – Comirnaty and Paxlovid. Clarity on the underlying vaccination and treatment rates will be observed by year end and will set a reliable base for the prediction of future product utilization.
As previously announced, the European Union (EU) contract for Comirnaty supply was renegotiated with amended purchasing obligations through 2026. The U.S. market for Comirnaty transitioned to commercially available product in September 2023. Due to the recent commencement of the fall vaccination period, the outlook for year-end vaccination rates and market shares requires more time for more determinable estimates.
As previously announced, Paxlovid also received full NDA approval from the FDA earlier this year. The global utilization rates for Paxlovid are currently trending slightly above last year’s utilization but lower than our original expectations.
Launches Cost Realignment Program
In addition, in the fourth quarter of 2023, Pfizer announced that the company has launched a multi-year, enterprise-wide cost realignment program that will realign its costs with its longer-term revenue expectations. The program is expected to deliver targeted savings of at least $3.5 billion, of which $1.0 billion is expected to be realized in 2023 and an additional $2.5 billion is expected to be realized in 2024. The one-time costs to achieve the savings associated with the new cost realignment program are expected to be approximately $3.0 billion, of which the majority is expected to be cash. These costs will primarily include severance and implementation costs. Pfizer will continue to refine the estimated targeted savings and their associated costs over the remainder of the year and will incorporate them into its full-year guidance for 2024.
Updates Full-Year 2023 Revenue and Adjusted(2) Diluted EPS Guidance(1) Ranges
Pfizer also announced that it now anticipates full-year 2023 revenues to be in the range of $58.0 to $61.0 billion, versus its previous guidance range of $67.0 to $70.0 billion solely due to its COVID products. Full-year 2023 revenues for Paxlovid and Comirnaty are expected to be approximately $12.5 billion, a decline of $9.0 billion versus original expectations. The company is reducing its full-year 2023 revenue expectations for Paxlovid by approximately $7.0 billion which includes a non-cash $4.2 billion revenue reversal for the return of the 7.9 million treatment courses of EUA-labeled U.S. government inventory, as well as the delayed commercialization to January 2024 versus our previous expectation of commercialization in the second half of 2023. The company is also reducing its full-year 2023 revenue expectations for Comirnaty by approximately $2.0 billion due to lower-than-expected vaccination rates.
Pfizer’s non-COVID products remain on track to achieve an expected 6% to 8% operational revenue growth year over year in 2023.
Due to lower-than-expected utilization for our COVID products, Pfizer recorded a non-cash charge of $5.5 billion to Cost of Goods Sold in the third quarter of 2023 primarily related to inventory write-offs for Paxlovid of $4.6 billion and to a lesser extent for inventory write-offs and other charges for Comirnaty of $0.9 billion.
The company expects to deliver approximately $1.0 billion in savings in 2023 through its cost realignment program.
Revised guidance also reflects anticipated improvement in our Effective Tax Rate on Adjusted(2) Income for 2023 from approximately 15% in our original guidance to approximately 12%.
Due to the aforementioned items, the company now expects full-year 2023 Adjusted(2) diluted EPS to be in the range of $1.45 to $1.65 versus its original guidance range of $3.25 to $3.45.
SAY. NO. MORE.
Too bad one can only 'like' comments a single time.
I object to the framing of SV40 as a “contaminant” the exact same way it was done with the polio vaccines. It is an intentionally included compound designed to cause cancer, just as it is doing.
Special K - Nepetalactone, histoplasmosis and the truth shall set you free.
Thank you!
Thank you for everything you are doing.
https://open.substack.com/pub/igorchudov/p/pfizer-may-go-bankrupt-financial?r=jkey3&utm_medium=ios&utm_campaign=post
They've already made their billions+!!
I liked Swift better when she was used as a poster child on Twitter doing a roman salute